Nissen

Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023

RADNOR, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced financial results for the quarter ending September 30, 2023, and provided a corporate update.

Key Points: 
  • ET –
    RADNOR, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced financial results for the quarter ending September 30, 2023, and provided a corporate update.
  • Research and Development (R&D) expenses were $22.5 million for the quarter ended September 30, 2023, compared to $6.1 million for the quarter ended September 30, 2022.
  • General and Administrative (G&A) expenses were $3.8 million for the quarter ended September 30, 2023, compared to $1.4 million for the quarter ended September 30, 2022.
  • Net loss was $22.8 million for the quarter ended September 30, 2023, compared to $6.7 million for the quarter ended September 30, 2022.

Aplos Medical Achieves a Major Milestone in GERD Treatment with Omega PF™

Retrieved on: 
Friday, November 3, 2023

EDEN PRAIRIE, Minn., Nov. 3, 2023 /PRNewswire/ -- Aplos Medical (formerly CT Resources), developer of the next generation Gastroesophageal Reflux Disease (GERD) treatment, proudly announces the successful first implantation of its revolutionary Omega PF™ device.

Key Points: 
  • EDEN PRAIRIE, Minn., Nov. 3, 2023 /PRNewswire/ -- Aplos Medical (formerly CT Resources), developer of the next generation Gastroesophageal Reflux Disease (GERD) treatment, proudly announces the successful first implantation of its revolutionary Omega PF™ device.
  • The Omega PF™ device heralds a paradigm shift in GERD treatment.
  • "We are delighted by this monumental achievement, performed by Dr. Buckley and his team," Aplos Medical President and CEO Dr. Claude Tihon said.
  • "The simple Omega PF™ device is designed to mitigate common issues seen with current GERD treatments.

Nurses looking to build their careers in the pharmaceutical industry now have a path forward

Retrieved on: 
Tuesday, June 20, 2023

The CNMAP™ program is the first of its kind, establishing the industry standard for nurse professionals seeking entry into the industry, or looking to expand their skillset and careers in the biopharmaceutical industry.

Key Points: 
  • The CNMAP™ program is the first of its kind, establishing the industry standard for nurse professionals seeking entry into the industry, or looking to expand their skillset and careers in the biopharmaceutical industry.
  • Nurses have deep medical expertise and are critical thinkers, skills that are highly valued and transferrable in the pharmaceutical industry.
  • Former pharmaceutical executive and nurse, Janice Nissen who has over 30 years in the pharmaceutical industry said, "CNMAP will bring tremendous value for nurse professionals that are looking to build their careers as medical affairs or medical science liaison professionals in the biopharmaceutical industry.
  • This certification program signifies ACMA's commitment to equipping nursing professionals with the tools and knowledge they need to thrive in the dynamic landscape of medical affairs.

Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023

Retrieved on: 
Thursday, June 8, 2023

Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there.

Key Points: 
  • Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there.
  • Because when it comes to high cholesterol, getting to goal is not optional.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.
  • More than 60,000 people will have participated in the program by the time of its completion.

What BBC and Stan series Ten Pound Poms gets right – and wrong – about the British migrant experience in Australia

Retrieved on: 
Friday, May 12, 2023

As snow falls against a grey sky in Manchester, Terry Roberts (Warren Brown) works to repair buildings damaged during the second world war.

Key Points: 
  • As snow falls against a grey sky in Manchester, Terry Roberts (Warren Brown) works to repair buildings damaged during the second world war.
  • Set in 1956, Ten Pound Poms, a co-production between the BBC and Stan, tells the story of British migrants as they struggle to build new lives in a distant and unknown land.

Australia’s post-war migration program

    • The “Ten Pound Pom” scheme was launched in 1945 and continued into the early 1970s.
    • Australia’s post-war migration program was driven by the imperative to “populate or perish”.
    • Australia was still a British country and a proud member of the British Empire, with a preference for British migrants.

A new life?

    • But once they arrive in Australia, their dream of a new life is dealt a blow.
    • As assisted migrants, they are sent straight to a migrant hostel camp, where they will live while earning enough to pay their own way.
    • Most assisted migrants who arrived by ship ended up in these camps, where they could stay while they looked for work and resettled.
    • Instead they make only brief appearances, and even then, often as caricatures, such as the lazy and overly-emotional Italian, Maria (Sarah Furnari).

An imperial past

    • But Ten Pound Poms gives us an idealised portrayal of the migrants’ relationship with Ron and the other Aboriginal characters.
    • Series writer, English screenwriter and playwright Danny Brocklehurst, rightly points out these migrant stories are an important aspect of Australia’s past that have received little attention.
    • But equally important is that this remembering takes account of both Britain and Australia’s imperial past.

If the camera was there with the blessing of Father Bob Maguire, people felt safe: my relationship with a marvellous man

Retrieved on: 
Monday, April 24, 2023

Very aptly, the charitable foundation Father Bob established in 1979 was named the Open Family Foundation.

Key Points: 
  • Very aptly, the charitable foundation Father Bob established in 1979 was named the Open Family Foundation.
  • Father Bob and his team of outreach workers took me with them into derelict squats, seedy back alleys, soup kitchens and dumpster bins.
  • Initially, she wanted her face blurred on camera, but after five minutes she changed her mind and became quite expansive.
  • If the camera was there with the blessing of Father Bob or his team, people felt safe.
  • Read more:
    Religious groups are embracing technology during the lockdown, but can it replace human connection?

‘They are one of us’

    • “The most Christian person I have ever met is a Jewish pugilist,” said Father Bob of his protégé.
    • A figure would emerge from the shadows and in the gentlest of voices, Henry would call: “Is that you X….
    • One of the songs, Down City Streets, was written by Roach’s partner, Ruby Hunter, about her experience as a street kid.
    • Read more:
      Archie Roach: the great songman, tender and humble, who gave our people a voice

transcosmos inc. offers 5A Diagnostics service to Nissen Holdings Co., Ltd.

Retrieved on: 
Monday, April 10, 2023

TOKYO, Japan, April 10, 2023 /PRNewswire-PRWeb/ -- transcosmos inc. hereby announces that the company has offered its 5A Diagnostics service to Nissen Holdings Co., Ltd. (President and Representative Director: Jun Habuchi).

Key Points: 
  • TOKYO, Japan, April 10, 2023 /PRNewswire-PRWeb/ -- transcosmos inc. hereby announces that the company has offered its 5A Diagnostics service to Nissen Holdings Co., Ltd. (President and Representative Director: Jun Habuchi).
  • In 2019, transcosmos began assisting Nissen Holdings in developing strategies to achieve their goal by offering 5A Diagnostics, a service that uses a unique metric proposed by Professor Philip Kotler and is specifically designed for diagnosing customer loyalty.
  • transcosmos performed competitive analysis along the 5A's customer journey while visualizing key customer needs at the same time, thereby successfully helping Nissen Holdings develop its strategy.
  • In 2022, transcosmos expanded service coverage to include customer experience (CX) diagnostics, and named the service the 5A Loyalty Diagnostics, enhancing its loyalty marketing strategy.

Implantica Announces RefluxStop Launch in Spain

Retrieved on: 
Monday, March 6, 2023

The first results indicate that RefluxStop can cure reflux in 95% of cases without the need for medication.

Key Points: 
  • The first results indicate that RefluxStop can cure reflux in 95% of cases without the need for medication.
  • "We are proud to accomplish this milestone for RefluxStop, as the beginning of a strong territorial business expansion in key European markets in 2023.
  • We look forward to continuing our collaboration and helping improve patients' quality of life," says Dr. Peter Forsell, Founder & CEO of Implantica.
  • Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC

Retrieved on: 
Monday, February 20, 2023

Hyperuricemia may occur early in treatment and persist throughout treatment, and may lead to the development of gout, especially in patients with a history of gout.

Key Points: 
  • Hyperuricemia may occur early in treatment and persist throughout treatment, and may lead to the development of gout, especially in patients with a history of gout.
  • Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.
  • Drug Interactions: Simvastatin and Pravastatin: Concomitant use results in increased concentrations and increased risk of simvastatin or pravastatin-related myopathy.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.

Kalera Outlines New Strategy and Path to Profitability

Retrieved on: 
Thursday, September 22, 2022

The product line extensions will maximize Kaleras revenue potential and farm capacity utilization, according to Chief Financial Officer Fernando Cornejo.

Key Points: 
  • The product line extensions will maximize Kaleras revenue potential and farm capacity utilization, according to Chief Financial Officer Fernando Cornejo.
  • Local partners will provide financing to develop the farms while Kalera runs the farms design, construction and operation.
  • Dr. Jade Stinson, Co-Founder and President of Vindara, Inc., a subsidiary of Kalera, highlighted Kaleras vertical integration all the way back to the seeds.
  • Kalera is headquartered in Orlando, Florida with farms in Orlando;Atlanta, Georgia;Houston, Texas;Denver, Colorado; andKuwait, with additional farms under development.